10 thematic workbooks describing the national situation on drugs in France in 2023.
This briefing paper presents an overview and traces the main developments in the chemsex phenomenon in France over the past fifteen years.
This briefing paper aims to identify trends, and emerging and/or less widespread phenomena in the use of illicit drugs in Martinique in order to contribute to the understanding and knowledge of their developments in the longer term.
The OFDT presents the results of a survey on professional practices and care pathways for alcohol users within three medical addiction microstructures (MSMA).
This year, 132 specialised drug treatment centres (CSAPA) participated in the RECAP survey (common data collection on addictions and treatments), out of a total of around 500 CSAPAs, providing data on more than 210 000 patients.
This document provides an overview of the supply, uses, and the social and health consequences of alcohol consumption in France in 2022.
Behavioural addictions still make up a scientific and clinical field under construction, characterised by a low consensus level which results in large numbers of concepts, terms, definitions and measuring tools.
The study on the use of analgesic opioid medicines (EMOA) by the French Monitoring Centre for Drugs and Drug Addiction (OFDT) examines their prescription in general practice and the experiences of who consider themselves to be having difficulty with them in the treatment of chronic pain unrelated to cancer in France.
This review of the social science publications on trajectories to quit smoking begins with an account of surveys looking at methods used to help smokers quit and professionals involved in helping them. The second part of the report deals with studies analysing the impact of socioeconomic variables on smoking behaviour and/or cessation.
The French Monitoring Centre for Drugs and Drug Addiction (OFDT) publishes the first results of the Study on the use of analgesic opioid medicines (entitled EMOA).
The aim of this document is to present updated data on opioid substitution treatment in France. It is based on the latest available data, the year of which may vary from 2019 to 2022 depending on the source and the treatment period.
This report of the RECAP survey (common data collection on addictions and treatments) reviews the main recent changes in the statistics on people with addictive behaviour problems accompanied and cared for by teams from specialised drug treatment centres (CSAPA in French).
This briefing from the French Monitoring Centre for Drugs and Drug Addiction (OFDT) provides an overview of the supply, uses, and the social and health consequences of alcohol consumption in France in 2021.
The OFDT publishes this issue on the analysis of the practices of addiction treatment workers: what does it mean to work in specialised drug treatment centres (CSAPA) and in harm reduction facilities (CAARUD)?
This 2022 edition provides an overall perspective digest in 8 pages with the most recent and detailed facts and figures.
This overview describes and evaluates the current crack cocaine situation in Île-de-France in order, in particular, to improve the treatment of users and, more generally, the response of the public authorities to a phenomenon that has been identified for around thirty years.
The aim of this Théma is to provide an overview of the situations and problems currently observed in the French overseas territories with regard to drugs and addictions, based on the most recent statistical data and the main studies carried out in these territories.
The 2019 edition of the annual OFDT overview on tobacco describes the repercussions of successive rises in prices of tobacco in the tobacconist network and the continuous increase of the number of people following a treatment to stop smoking.
This summary covers the main contributions from a collective OFDT publication entitled "Drogues et addictions, données essentielles" issued in April 2019.
As a minority in specialised care services, French women presenting with addictions represent 23% and 18% of the public seen in specialised drug treatment centres (CSAPA) and harm reduction facilities (CAARUD) respectively.